Share Name Share Symbol Market Type Share ISIN Share Description
Realm Thera. LSE:RLM London Ordinary Share GB00B3XBCR18 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 34.50p 33.00p 36.00p 34.50p 34.50p 34.50p 0 07:49:51
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.7 -5.9 -0.8 - 47.51

Realm Thera. Share Discussion Threads

Showing 26 to 48 of 50 messages
Chat Pages: 2  1
DateSubjectAuthorDiscuss
29/3/2018
21:44
New realm thread with charts and information
haroldthegreat
12/3/2018
12:24
Disappointing and rather surprising news this morning and it will be interesting to see Martin's webcast presentation at the Cowen conference tomorrow. Had not expected abondonment so soon; of course 13 had less financial potential than 22 and what they said today that there is no crossover between 13 and 22 is that the prospects for 22 are unchanged with this news reflects my previous understanding. This will mean I assume that they will have finance to progress 22 that much further. I am assuming that 13 dry eye which is in preclinical is not affected; note no mention perhaps means that not regarded as important. One downer is that 13 was ahead of 22 so if things had gone without a hitch would have generated revenue sooner. Pleasantly surprised that there has been so much liquidity and have lightened up a bit.
cerrito
15/2/2018
10:33
Positive clinical and business update released today and new research note with valuation update now out from Equity Dev. Free access here: https://www.equitydevelopment.co.uk/company/?company=Realm+Therapeutics&c=xUTO … AND you can see the CEO of Realm present at the next ED Private Investor Forum in London on Wed 28 March, register here: https://www.eventbrite.co.uk/e/equity-development-investor-forum-march-2018-tickets-43192146874?ref=elink
edmonda
30/1/2018
20:54
The presentation given at the ProActive session in London and the earlier one in the US can be found here hxxp://docs.wixstatic.com/ugd/4e4ab6_e8e60bce5bf34de3b4982548b0ec73ef.pdf
cerrito
15/1/2018
13:07
Realm Therapeutics will be presenting to investors at the upcoming Proactive One2One Forum on the evening of 25th January in London. For details and registration, please click here: https://tinyurl.com/yca3olxy
aim_trader
22/12/2017
16:36
Equity Development have published a new clearly written note on RLM hxxps://www.equitydevelopment.co.uk/edreader/?d=%3D%3DwM3MjM ED reckon RLM have cash till Q3 19; there are now 3 preclinical programmes and on one RLM023 we are told to expect in late 2018 a IND filing. On PR022 we should get a read out on the current Phase IIa in Q3 18 and on PR013’s phase IIb in Q2 18. They have a valuation of 110p per share which I take with a pinch of salt as it is still early days. So no hard news for 6 months +; given the lack of market activity-as far as I can see only 120k shares traded since November 22- we need to be prepared for the price to drift down given boredom.
cerrito
16/11/2017
22:40
The price fall of the last few days has come with little volume: Volume for the first three days of this week were 45k, 85k and 5k.
cerrito
22/10/2017
19:02
Thanks smraynot for setting up this new thread. Noted it made yesterdays's FT Small Cap Focus...which was inaccurate referring to a £16m marcap rather than a £50m one.
cerrito
19/10/2017
17:49
Wonderful webcast yesterday. With quality management and positive phase 11 trials this share could absolutely rocket. My short term target in excess of £5.
smraynot
18/10/2017
14:21
very surprised and very pleasantly so by the share price increase today
cerrito
16/10/2017
15:52
The costs for this last fund raising seem very high but they did get 4 new investors to take 55m of the 66m new shares. PS are there holders who can set up a new thread?
cerrito
15/10/2017
23:02
Just seen that this last equity raise seems very expensive ie expenses of £1.6m for a raise with a gross value of £19.3m. Would total expenses have been so high in NYC?Reinforces the question as to why they are not in NYC given their 100% US and $ focus.
cerrito
23/9/2017
17:23
Nothing to surprise me in the interims and there does not appear to be any time slippages:I was however surprised by the equity raise. Given their current cash burn they have enough to continue to middle of next year when they are due to announce their top line data readout for both programmes and on the basis that al least one-preferably PR022- is positive then the share price should be much higher. Not sure if I will be able to make the conference call
cerrito
11/9/2017
07:56
Good news today on PR013 and that they seem to be on schedule outlined in November last year to commence clinical trials this year.
cerrito
02/8/2017
19:21
Good that they meet their target to submit IND approval in Q3 for PR013; also good that still expecting to start PR022 Phase II this year. See that today’s news moved the share price up abit-only 15K-ie £5k- of shares traded which actually is equal to the total trades of the last 16 days-so illiquid are the shares. Of course FX rate a big factor in setting the share price and current weakness reflects $ weakness against the £. Also makes one wonder why this US company has a quote on AIM;I bought this up at the AGM and got reasonable reassurance on this. Happy with what I have and no current plans to buy or sell
cerrito
24/3/2017
20:46
I see the price has dropped following the full year figures and AR, though I cannot think why as nothing new..perhaps it was the results call...anyone hear it??
cerrito
13/3/2017
21:03
FT has two articles on fact that FDA about to approve Sanofi/Regeneuron's dupilumab-as has been anticipated by RLM. Remember PR022 is for the mild to moderate market and dupilimab for the moderate/severe. https://www.ft.com/content/ac4f2990-05cf-11e7-ace0-1ce02ef0def9 is interesting on pricing aspects
cerrito
28/2/2017
19:31
Market rather yawned at Realm's news this morning; I know that for operational reasons they were very keen to get this permission quickly which they have done.
cerrito
30/1/2017
13:32
If you would like to listen to the presentation given by CEO Alex Martin at our previous investor forum the recording is now available at: hxxps://www.equitydevelopment.co.uk/webinars/?d=%3D%3DQO1IjM Kind regards, The Equity Development team
hannahh
26/1/2017
13:19
Yes be good if anyone who follws RLM and who has the ability to set up a new board can do so. I will try and write up meeting last night and Equity Development have produced a (to me) V informative note.
cerrito
26/1/2017
00:53
Is this BB going to morph into a Realm Therapeutics BB?
gnnmartin
17/1/2017
14:12
If you would like to hear Alex Martin, Chief Executive Officer, present on behalf of Realm Therapeutics he will be appearing at our next investor forum on the evening of Wednesday 25th of January. Also appearing will be the management of Ergomed and Kromek. To learn more about the forum and to register for free please follow this link: hxxps://www.eventbrite.co.uk/e/equity-development-investor-forum-january-2017-tickets-30349576400 Thanks, The Equity Development team
hannahh
15/9/2011
20:40
SLE mid price 22.125p = C$1.16 per RLM share.
buffin
Chat Pages: 2  1
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:32 V: D:20180424 10:21:21